

## Original Article

# Propofol increases Bcl-2 Levels to protect cell from death

Luowa Shu<sup>1\*</sup>, Zhiya Chen<sup>2</sup>, Chuxiong Pan<sup>1\*</sup>

<sup>1</sup>Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;

<sup>2</sup>State Key Laboratory of Membrane Biology, College of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing 100871, China. \*Equal contributors.

Received September 12, 2016; Accepted September 19, 2016; Epub November 15, 2016; Published November 30, 2016

**Abstract:** Bcl-2 is an important gene of apoptosis research, during the past decade, there has been an increasing interest in the relationship between Bcl-2 and the apoptosis, but only a few studies talk about the relationship between Bcl-2 and propofol, which is a wild use narcotic that can protect cells against various injuries. In the present study, we showed that propofol could down-regulate miR-297a-5p to increased Bcl-2 level. We think this might be a possible mechanism of propofol protecting cell from death. Furthermore, we use an apoptotic drug staurosporine to further improve the propofol's cell protecting function by showing that propofol prevented neurons against staurosporine. Our study supplies a possible mechanism that propofol could regulating Bcl-2 level through miRNA to protect cells.

**Keywords:** Propofol, microRNA, anesthetics, cell death, Bcl-2

## Introduction

Bcl-2 family proteins are very important in the regulation of apoptosis, tumorigenesis and cellular responses to anti-cancer therapy, which has been studied intensively for the past decade owing to their importance in the regulation of apoptosis [1, 2]. At the same time, propofol (2, 6-disopropylphenol) is a widely used intravenous short-acting anesthetics [3], which has been also reported in protecting against cerebral ischemia or ischemia-reperfusion, intracerebral hemorrhage, cerebral resuscitation, ischemia of spinal cords, Parkinson's disease (PD) and Alzheimer's disease (AD) [3, 4], but we still don't know the exact mechanisms of propofol's protection. MicroRNAs (miRNAs) are a group of short non-coding RNAs [5]. There are more than one thousand miRNAs identified in mammals [6]. 3'UTR or 5'UTR area interact with a single-stranded miRNA which are the miRNA precursors [7], leading to translation repression or target degradation [8, 9], by miRNAs which regulate the protein level of the target genes. A single miRNA can conjugate with several hundred target genes, therefore, it may regulate multiple pathways at the same time

[10, 11]. Many miRNAs have demonstrated implications in anesthesia [12-16]. We have a previous study showing that various miRNAs transform propofol treatment into cultured primary mouse hippocampal neurons. After examining 1908 mice microRNAs, we found that there are 40 microRNAs upregulated and 54 microRNAs downregulated with the cutoff as 2 fold change [17].

According to the present study, we reported that in the hippocampal neurons of mice, microRNA named miR-297a-5p, which targets Bcl-2 mRNA 3'UTR, is highly down-regulated with propofol treatment. In addition, we also showed that propofol prevents neuronal from cell death, possibly through reduction in the level of miR-297a-5p. Our results indicate that microRNA regulation is a critical determining factor of propofol protection mechanism.

## Experimental procedures

### Cell culture and treatments

We culture the primary neurons by using wild type C57 mouse hippocampus, and follow the regulations of Peking University Animal Care

## Propofol prevents cell death

and Use Committee as previously described [18]. In brief, we dissociated the fresh fetal mouse hippocampal tissues into 0.25% trypsin (Invitrogen, Carlsbad, CA) by 20 minutes, then used Dulbecco's Modified Eagle Media (DMEM) mixed by 10% fetal bovine serum (FBS, HyClone, Logan, UT) to terminate. Then the mixture was put in a stationary state for a few minutes, and transferred into another sterilized centrifuge tube and then finally was centrifuged. The pellet was recoiling by 10% FBS. Cells were then plated on poly-L-lysine (Sigma, St. Louis, MO) coated plates or glass coverslips at the density of  $3 \times 10^6$  cells/ml and added 2 ml neurobasal medium along with B27 (Gibco, 17504-044), GlutaMax (Gibco, 35050-061), and Pen-Strep (Gibco, 15140-22) for every well after 30 minutes. Neurons were incubated in 5% circulating CO<sub>2</sub> at 37°C. Half of the medium was changed every 48 hours. Neurons were treated for experiments at the 7th day in culture. Propofol was added to the medium at 100 nM for 6 hours.

### Real-time PCR

We do the real-time PCR as as per the following procedure described previously [19]. We measured miR-297a-5p in the tissue, serum and cerebrospinal fluid (CSF) by TaqMan MicroRNA assay kit according to the manufacturer's instruction (Life Technologies Corp.). In brief, we collected cells and isolated total RNA with TRIgene reagent (GenStar BioSolutions Co., Ltd., Beijing, China). Then reverse transcription was done to be total RNA (2 mg) by using TransScript II First-Strand cDNA Synthesis SuperMix (Beijing TransGen Biotech Co., Ltd., Beijing, China). We only used TransStart Green qPCR SuperMix UDG (Beijing TransGen Biotech Co., Ltd., Beijing, China) to do the real-time PCRs. We ran the sample as triplicate and determine the average for real-time PCR quantifications. In order to use the Ct method to compare the relative quantification, the amplification efficiency of target and housekeeping gene must be approximately equal. After using the comparative Ct method to finish quantification, we normalized the expression levels for the target gene by the GAPDH of each sample [ $2^{-\Delta Ct} = 2^{-(Ct(\text{target gene}) - Ct(\text{GAPDH}))}$ ]. Amplification was done for 45 cycles at 95°C for 30 s, 59°C for 30 s, 72°C for 30 s, 95°C for 1 min, 59°C for 30 s and 95°C for 30 s.

### Sources of reagents and sequences of miRNAs and 3'UTR

Mouse miR-297a-5p (5'-AUGUAUGUGUGCAUGUGCAUGU-3'), scramble microRNA control (5'-GTGTAACACGTCTATACGCCCA-3'), mimic miR-297a5p (5'-UUGGAAGGGCGTCTAUGCAUGU-3'), miR-297a-5p inhibitor (5'-AACCUUCCCGUAUGACGUACA-3') and mutant miR-297a-5p (5'-AUGUAUGUGUGCAUGACGUACA-3'), complementary sequence (5'-ACATACA-3') were all purchased from Qiagen. Several altered mouse Bcl-2 mRNA 3'UTR sequences used were as following: mutant Bcl-2 mRNA 3'UTR: 5'-TGTATGT-3'; MAP2-3'UTR: 5'-CATATTCATTCTTTACAAACCATAG-3'. All WT and modified 3'UTR sequences were cloned into pLenti-Luc-UTR or pLenti-EGFP-UTR vector backbone (Abm). MicroRNAs were transfected into SH-Sy5y cells with HiPerFect Transfection Agent (Qiagen).

We used the 100× stored propofol (Sigma) and staurosporine (STS, Sigma) and diluted with the culture medium before using it. One month old C57 mice were treated with propofol (200 mg/kg) by intraperitoneal injection (i.p.). Cultured cells were treated with 2% propofol for 6 hours before assays.

### Western blots and measurement of neuronal cell death

We do western blots by following the protocol described previously [18]. In brief, we diluted anti-Bcl-2 (Abcam) and actin (Sigma) antibodies at 1:1000 for Western blots as primary antibodies. Because actin is the house keeping gene, the relative density was calculated by the total absolute density of Bcl-2/actin control. We measured the cell death with terminal deoxynucleotidyl transferase-biotin dUTP nick-end labeling (TUNEL) staining performed using the *in situ* cell death detection kit I which described by the manufacturer (Roche) [18].

### Luciferase reporter assay

We used the Dual-Luciferase Reporter Assay System kit (E1910, Promega) to investigate the effect of miR-297a-5p on Bcl-2 expression. In the meantime, we used co-transfected with the wild-type, mutant, scramble, mimic and inhibitor to miR-297a-5p into SH-Sy5y cells as the constructs of the firefly (*Photinus pyralis*) luciferase gene downstream of the Bcl-2 3'UTR.

**Mmu-miR-297a-5p**

AUGUAUGUGUGCAUGUGCAUGU

**Bcl-2 mRNA 3'UTR**

```

3061 ATCGAGAAGA GCAGCCCAAT GCCCTCCAGA GCCCCAGTAC CCGCCAGGC TCTCTGAGAG
3121 ATGGCAAAAA AAACAGAGAG GTTGATCTTC AGTGATTCCT CAGGGCCTGA ACTTGCCTGA
3181 AGGCTTGAGA TGTCATGAG AGCCACAGTT AAGGGAGCAC TTTTCATGTAG TTCAAGTAAA
3241 ACCCTCCATC CTGTCCAGCT CGCTTGTCTC TGGATGTTTG GGTGTGGCCT TTATTCATAC
3301 ATACATACAT TTTTCCACA GGCATATCT TATTTATAC ATCTAAGAGC ATTGCTGGGT
3361 CTAGGAAAAGG GGGGAGCAGG GTTTAGGAAAG TGCTCATAAG CCAGGAGGGA TTATAATAAT
3421 CAGGACTGAA TGTAGATAAT GGGTGGCAGT ACCCACATGT GTAGGTCCCA CACTGAATAG
3481 AATAGGCAGA ATTTGTAATA GCCCGTGTTC GTAATGGAGC CTAGACTAAA ACAACTCATA
3541 AATGTGAGCT TCAACTCTAA CTGTGCTTTG AAGGTGATGG GTGTCTCTAT ACTTCTCTAT
3601 CAGTTACAGT TAGAATGTGA CACCTACCCT ATCAGGAAAA AATAACAGGA AAAGGTTGAA
3661 ATATAAGCCA GTCTAAGGAA ATTAGGGAGC CACTAAAGTT CTCTTCTGAG CTTACTACTAT
3721 GGTCTCTATT GCAGCTCAGA CAAATATGAT CACACACTTT TTAAGAAATA CAATTCTCCA
3781 TTGTCCGGCC CATGAAGGCT CTGATCTGAT CTGTATTGTT GCCCAATTTG GGTCTTTCAG
3841 GGATTTTTCT ATGCCATTAT TATAGGGACA AAGGACACTT GTTATGAGGT GGGAGAGATG
3901 AAGAATTCTT AAGTAAAGTAG AACATTTCT AGATTGGGCC AGGGTGTGAA GGTCTCAGC
3961 AAAATCAAGG CTGTGAGAAG TGAGGGACCT TTATGGGGGT CAAAGTTATG TTCGCCGAG
4021 GACTTTTTCG AAGAAGCAAG GAAGCTCTAT GGTACATTTA TACTCCAGGG ACATTGACCT
4081 AGTTCAAAGT CTGGCTTAAT ATGGTCAAGC AATAGCATAT GTTCAAGTT GGATATGGCT
4141 AATGAGTGT TAAACAGTAA GTTTGACATT TTAACCAACA GGGTATTAA ACAACAACCT
4201 TCCAGTTGGT AGGGACATCT GTTTCTCTCT GTTTATTATA CACAACATAG AAAAAATTCA
4261 ATAAGATTGA ATTAAGTAAA ACATTGTGAG ACTGAGTTAG GTAAACGATT GTGGCAGTCC
4321 CTTAGCCTTG GCCAGGGAAT TATTCAATCC GCTATAGACA TCTGTGCACT GTGCATCTCT
4381 CCAGGCATGA AGAAAAACCA GTAGAGGGCA GATGGCACCT GAGCACTCA TCCTGGATAT
4441 CTAAGAAGAA TAACATAAAG CAGTGTTC ATGCACCAAG TCCAGTACAG AAGACAAAAA
4501 GAGTCAAGA AGATGAAAA GCTAGCTAAT CAGAAATCCT GGAATGTGA AGTGTGCCGG
4561 CCATGTGGCT ATGCGGCAAT GCCTGTACCT TCCCACTTGG GAACCTGCG TGGGCCCTCC
4621 AGCTGGCTCC CTTTCATGAAA TCCTCCCTC CGAGATAACA TCTGAAGGAT TGATGGCAGA
4681 TTCAGTTTCC ATTAGGAGAT ATTTTCTTT GGAGACAGGG GTTCTCTATT AAAATATCTT
4741 CTTAGTTTT CAGTAAACT TTGCTTTGGC TTAGCTATA GTGGGTTCT TCTAAGTAA
4801 AGTAATGTT AAATAAGTGT TTTGTATTGG AAGCTTTGTT ATCAAGATT TCATACTTAT
4861 ATCCATGGGC TGCTTTTAAAG GTTGATACTT TTAGGCGTGG CTGATGCTA TAGCACTGTA
4921 CATAAGAA ATATATAAGT GTATTTGGCA TACTTAAGGT AAAATAAGTC TCCAGTTGGC
4981 TACTGTTACA TATAATGGCT CTTTGTGTT GTTGTAGAA AACATTACAT TGCCATTAAC
5041 TCCCATGTC TGCTGAAAA AATAAAATAA AATACAGTGA GCAGCAAAAA AAAAAAAAAA
5101 AAA

```

**Figure 1.** Sequence alignment of mouse miR-297a-5p and Bcl-2 mRNA 3'UTR region. The red highlighted parts shows the complementary regions.

As indicated by the manufacturer, firefly luminescence was detected. In order to control the transfection efficiency, the *Renilla reniformis* luciferase construct was co-transfected into the cells. The activity was corrected for the protein concentration of each sample and expressed as [(firefly/renilla luciferase) \*10,000]. The luminescence was expressed as relative light units [20].

#### Statistical evaluation

We used one-way analysis of variances (ANOVA) by the Sheffé's test which has statistical significance. A *p* value of less than 0.05 indicated statistical significance.

#### Results

##### *Bcl-2 mRNA 3'UTR was a target of miR-297a-5p*


According to the miRNA target prediction tool website (<http://www.microna.org/microna/>

home.do), one complementary sequence for miR-297a-5p is present in the 3'UTR of Bcl-2 mRNA in mice (Figure 1, highlighted with red). After treating it with propofol in the hippocampal tissues which came from 1 month old mice, miR-297a-5p was decreased (Figure 2A). Previous studies have shown that miRNAs can be secreted into the CSF and plasma [21]. Therefore, we observed that miR-297a-5p levels were down-regulated in the CSF and plasma after propofol treatment (Figure 2A).

In SH-Sy5y cells, luciferase reporter assays were performed with the expression of firefly regulated by miR-297a-5p which is the complementary region of Bcl-2 mRNA 3'UTR, and used renilla as an internal control for transfection efficiency. We found that miR-297a-5p induced a dose-dependent inhibition of luciferase activity, whereas mutant miR-297a-5p and scramble control miRNA had no effect (Figure 2B). The mimic of miR-297a-5p obviously inhibited the luciferase activity, although the inhibitor of miR-297a-5p increased the luciferase activity (Figure 2B). In SH-Sy5y cells, EGFP reporter assay confirmed the similar inhibitory effect of miR-297a-5p to Bcl-2 mRNA 3'UTR (Figure 2C).

We then mutated the Bcl-2 mRNA 3'UTR complementary sequence and performed luciferase assay and EGFP reporter assay with both scramble control miRNA and miR-297a-5p. Our results showed that miR-297a-5p only suppressed the luciferase activity or EGFP fluorescence with WT Bcl-2 mRNA 3'UTR, but did not significantly inhibit with mutant 3'UTR (Figure 2D and 2E), which suggested the specificity of the interaction between miR-297a-5p and Bcl-2 mRNA 3'UTR. Further more, in order to further confirm that the Bcl-2 mRNA 3'UTR was one of the targets for miR-297a-5p, we mutated Bcl-2 mRNA 3'UTR with the putative complementary binding domain sequence (BD), 2 repeats of the BD sequence (2BD) and 3 repeats of the BD

## Propofol prevents cell death



**Figure 2.** Propofol was protective against cell death. A. After treating with propofol, miR-297a-5p was decreased in the hippocampal tissues, CSF and plasma in the mice. B. The dose response of miR-297a-5p on Luciferase reporter assay in SH-Sy5y cells. C. The dose response of miR-297a-5p on EGFP reporter assay in SH-Sy5y cells. D. MiR-297a-5p reduced the luciferase activity with WT Bcl-2 mRNA 3'UTR, but not with mutant Bcl-2 mRNA 3'UTR. E. MiR-297a-5p reduced the EGFP reporter activity with WT Bcl-2 mRNA 3'UTR, but not significantly with mutant Bcl-2 mRNA 3'UTR. F. MiR-297a-5p did not alter the expression with unrelated MAP2 mRNA 3'UTR. Within Bcl-2 mRNA 3'UTR constructed with 2 times or 3 times of the putative binding domain (2BD, 3BD) of each binding site, miR-297a-5p decreased luciferase activity remarkably in a dose dependent manner. G. Time course of miR-297a-5p inhibition on Bcl-2 mRNA 3'UTR. H. Western blot of Bcl-2 showed that mimic to miR-297a-5p (lane 2) reduced whereas inhibitor to miR-297a-5p (lane 4) increased the Bcl-2 level. Mutant miR-297a-5p (lane 3) did not alter Bcl-2 level. I. Statistics of H. Data represent Mean  $\pm$  SE (n=3 for each group). \*\*: P<0.01 compared with control. J. Western blot of Bcl-2 showed that propofol increased the Bcl-2 level. K. Statistics of J. Data represent Mean  $\pm$  SE (n=3 for each group). \*\*: P<0.01 compared with control. L. In cultured neurons, we compare the cell death rate results of several different treatments such as adding propofol at 2%, propofol at 2% and Bcl-2 inhibitor, STS only, STS and propofol at 2%, and STS, propofol at 2% and Bcl-2 inhibitor in the culture medium, we measured cell death 6 hours after treatment. Data represent Mean  $\pm$  SE (n=3 for each group). \*\*: P<0.01 compared with control.

sequence (3BD) for each putative binding site. Luciferase reporter system showed that miR-297a-5p did not inhibit the luciferase activity regulated by unrelated MAP2 mRNA 3'UTR (Figure 2F). Luciferase activity was greatly reduced in a BD dose-dependent manner where in Bcl-2 mRNA 3'UTR (Figure 2F). Time course study showed that luciferase activity was inhibited by miR-297a-5p from 12 hours after treatment and kept at almost the same inhibition levels after 12 hours (Figure 2G). Western blotting of total Bcl-2 with miR-297a-5p, inhibitor to miR-297a-5p, and mutant miR-297a-5p indicated that miR-297a-5p indeed decreased Bcl-2 protein level (Figure 2H and 2I), whereas inhibitor to miR-297a-5p increased Bcl-2 (Figure 2H and 2I).

### *Propofol prevent cell death by up-regulation the bcl-2 level*

It is well-known that Bcl-2 family proteins are involved in regulation of cell death, especially apoptosis [1, 2]. We then examined the vulnerability to various injury in cultured neurons with or without propofol treatment. Our data showed that STS could induce severe cell death in untreated neurons than in propofol treated neurons [22, 23]. After that, we did a western where western blot of Bcl-2 showed that propofol increased the Bcl-2 level (Figure 2J and 2K). In cultured neurons, neuronal toxicity was induced by STS, we compared the cell death rate results of five different treatments such as (i) adding propofol at 2%, (ii) adding propofol at 2% and Bcl-2 inhibitor, (iii) adding STS only, (iv) adding STS and propofol at 2%, and (v) adding

STS. Propofol at 2% and Bcl-2 inhibitor in the culture medium remarkably decreased cell death at 6 hours after treatment (**Figure 2L**).

## Discussion

As we know, the earliest metazoan that was analysed with regards to the Bcl-2 gene was the sponge [24], and so far Bcl-2 gene orthologues have been identified in all metazoan animals [25]. During the past few years, people found some viral gene products the signature helical fold of Bcl-2, where it functions in apoptosis regulation [26-28]. Moreover, propofol as an anesthetic has been widely used in short-acting anesthesia and protects cells against various insults by increasing level of Bcl-2, which is an anti-apoptotic protein, and decreasing the level of pro-apoptotic protein Bax. Our study has developed another possible mechanism, which is that propofol regulating Bcl-2 level through miRNA prevents cell death.

In studies with those mechanisms, we found that neurons with propofol treatment could cause miR-297a-5p to be down-regulated. Besides that, miR-297a-5p targets 3'UTR of Bcl-2 mRNA and the decrease of miR-297a-5p increases Bcl-2 level in neurons. Propofol could protect against cell death induced by STS. However the mechanism of propofol protection has not been made fully clear yet. One possible explanation is that propofol can decrease miR-297a-5p level, which targets 3'UTR of Bcl-2 mRNA and increases the level of Bcl-2. Because the activation of Bcl-2 reduces cell death and apoptosis, increasing Bcl-2 level could prevent cell death. Our current data showed consistency with the previous observation which is that propofol may reduce cell death through increase of Bcl-2 [29]. In conclusion, our study indicates that propofol could prevent cell death by up-regulation the Bcl-2 level through decreasing the miR-297a-5p level which target the 3'UTR of Bcl-2 mRNA.

## Acknowledgements

This work was supported by the National Science Foundation of China (NSFC) Research Grant (81301131, 81571037 and 81671044).

## Disclosure of conflict of interest

None.

## Authors' contribution

L.S., and Z.C. performed all the experiments and analyzed the data. C.P. conceptualized the study, performed analyses and drafted the manuscript.

**Address correspondence to:** Dr. Chuxiong Pan, Department of Anesthesiology, Beijing Tongren Hospital, Beijing 100730, China. E-mail: pande-dao@126.com

## References

- [1] Youle RJ and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. *Nat Rev Mol Cell Biol* 2008; 9: 47-59.
- [2] Delbridge AR, Grabow S, Strasser A and Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. *Nat Rev Cancer* 2016; 16: 99-109.
- [3] Fan W, Zhu X, Wu L, Wu Z, Li D, Huang F and He H. Propofol: an anesthetic possessing neuro-protective effects. *Eur Rev Med Pharmacol Sci* 2015; 19: 1520-1529.
- [4] Zhang Y, Zhen Y, Dong Y, Xu Z, Yue Y, Golde TE, Tanzi RE, Moir RD and Xie Z. Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Abeta oligomerization. *PLoS One* 2011; 6: e27019.
- [5] Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T. Identification of novel genes coding for small expressed RNAs. *Science* 2001; 294: 853-858.
- [6] Delay C, Mandemakers W and Hebert SS. MicroRNAs in Alzheimer's disease. *Neurobiol Dis* 2012; 46: 285-290.
- [7] Peters L and Meister G. Argonaute proteins: mediators of RNA silencing. *Mol Cell* 2007; 26: 611-623.
- [8] Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M and Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. *RNA* 2009; 15: 21-32.
- [9] Meister G. miRNAs get an early start on translational silencing. *Cell* 2007; 131: 25-28.
- [10] Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP. The impact of microRNAs on protein output. *Nature* 2008; 455: 64-71.
- [11] Selbach M, Schwanhaussner B, Thierfelder N, Fang Z, Khanin R and Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature* 2008; 455: 58-63.
- [12] Ishikawa M, Tanaka S, Arai M, Genda Y and Sakamoto A. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. *Anesthesiology* 2012; 117: 1245-1252.

## Propofol prevents cell death

- [13] Tanaka S, Ishikawa M, Arai M, Genda Y and Sakamoto A. Changes in microRNA expression in rat lungs caused by sevoflurane anesthesia: a TaqMan(R) low-density array study. *Biomed Res* 2012; 33: 255-263.
- [14] Werner W, Sallmon H, Leder A, Lippert S, Reutzel-Selke A, Morgul MH, Jonas S, Dame C, Neuhaus P, Iacomini J, Tullius SG, Sauer IM and Raschzok N. Independent effects of sham laparotomy and anesthesia on hepatic microRNA expression in rats. *BMC Res Notes* 2014; 7: 702.
- [15] Jiang XL, Du BX, Chen J, Liu L, Shao WB and Song J. MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1. *Int J Clin Exp Pathol* 2014; 7: 6760-6767.
- [16] Lu Y, Jian MY, Ouyang YB and Han RQ. Changes in rat brain MicroRNA expression profiles following sevoflurane and propofol anesthesia. *Chin Med J (Engl)* 2015; 128: 1510-1515.
- [17] Luowa Shu XY, Xu Cui, Dingxi Zhou, Junfa Li, Tianzuo Li, Chuxiong Pan. Propofol treatment alters microRNA profiling in neurons. *Int J Clin Exp Med* 2016; 9: 11292-11298.
- [18] Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, Chai Z and Zhang Y. Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. *J Neurosci* 2011; 31: 16227-16240.
- [19] Wang Y, Cui J, Sun X and Zhang Y. Tunneling-nanotube development in astrocytes depends on p53 activation. *Cell Death Differ* 2011; 18: 732-742.
- [20] Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifiro M and LeBlanc A. Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. *J Neurosci* 2004; 24: 5315-5321.
- [21] Chan AW and Kocerha J. The Path to microRNA Therapeutics in psychiatric and neurodegenerative disorders. *Front Genet* 2012; 3: 82.
- [22] Zhang Y, Goodyer C and LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7, and -8. *J Neurosci* 2000; 20: 8384-8389.
- [23] Cui J, Chen Q, Yue X, Jiang X, Gao GF, Yu LC and Zhang Y. Galanin protects against intracellular amyloid toxicity in human primary neurons. *J Alzheimers Dis* 2010; 19: 529-544.
- [24] Wiens M, Krasko A, Muller CI and Muller WE. Molecular evolution of apoptotic pathways: cloning of key domains from sponges (Bcl-2 homology domains and death domains) and their phylogenetic relationships. *J Mol Evol* 2000; 50: 520-531.
- [25] Aouacheria A, Brunet F and Gouy M. Phylogenomics of life-or-death switches in multicellular animals: Bcl-2, BH3-Only, and BNip families of apoptotic regulators. *Mol Biol Evol* 2005; 22: 2395-2416.
- [26] Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, Reed JC and Liddington RC. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. *Protein Sci* 2007; 16: 118-124.
- [27] Douglas AE, Corbett KD, Berger JM, McFadden G and Handel TM. Structure of M11L: a myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. *Protein Sci* 2007; 16: 695-703.
- [28] Kvensakul M, van Delft MF, Lee EF, Gulbis JM, Fairlie WD, Huang DC and Colman PM. A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. *Mol Cell* 2007; 25: 933-942.
- [29] Cui DR, Wang L, Jiang W, Qi AH, Zhou QH and Zhang XL. Propofol prevents cerebral ischemia-triggered autophagy activation and cell death in the rat hippocampus through the NF-kappaB/p53 signaling pathway. *Neuroscience* 2013; 246: 117-132.